|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 7/08 | |
| A61K 38/10 | |||
| A61K 38/16 | |||
| C07K 14/54 | |||
| A61P 3/00 | |||
| A61P 19/02 |
| (11) | Number of the document | 2764009 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12825032.1 |
| Date of filing the European patent application | 2012-08-21 | |
| (97) | Date of publication of the European application | 2014-08-13 |
| (45) | Date of publication and mention of the grant of the patent | 2017-12-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/AU2012/000977 |
| Date | 2012-08-21 |
| (87) | Number | WO 2013/026089 |
| Date | 2013-02-28 |
| (30) | Number | Date | Country code |
| 2011903358 | 2011-08-22 | AU | |
| 2011903360 | 2011-08-22 | AU |
| (72) |
PASPALIARIS, Vasilis, AU
LANGAN, Brett, AU
|
| (73) |
Paradigm Biopharmaceuticals Limited,
Level 2 517 Flinders Lane, Melbourne, Victoria 3000,
AU
|
| (54) | PEPTIDES FOR USE IN THE TREATMENT OF IL-1 RELATED DISEASES AND CONDITIONS |
| PEPTIDES FOR USE IN THE TREATMENT OF IL-1 RELATED DISEASES AND CONDITIONS |